» Articles » PMID: 26067992

Risk Factors for Early Mortality After AIDS in the CART Era: A Population-based Cohort Study in Italy

Abstract

Background: Despite the dramatically improved survival due to combination antiretroviral therapies (cART), life expectancy of people with HIV/AIDS remains lower than that of the general population. This study aimed to estimate, at a population level, the survival experience of Italian people with AIDS (PWA) and to quantify the prognostic role of selected factors at diagnosis in the risk of early mortality (i.e., within six months from AIDS diagnosis).

Methods: A population-based, retrospective-cohort study was conducted among Italian PWA diagnosed between 1999 and 2009 and recorded in the national AIDS registry. The vital status, up to December 2010, of 14,552 PWA was ascertained through a record linkage procedure with the Italian mortality database. Survival probabilities were estimated through Kaplan-Meier method. To identify risk factors for early mortality from any cause, odds ratios (ORs) and corresponding 95% confidence intervals (CIs), adjusted for major confounders, were computed using multivariate logistic regression models.

Results: Of the 5,706 deaths registered among the 14,552 PWA included in the study, 2,757 (18.9%) occurred within six months from AIDS diagnosis. The probability of surviving six months increased from 81.2% in PWA diagnosed in 1999-2000 to 82.9% in 2009, while the 5-year survival augmented from 60.7% in PWA diagnosed in 1999-2000 to 65.4% for PWA diagnosed in 2005-2006. Elevated risks of early mortality were associated to older age (OR = 5.28; 95% CI: 4.41-6.32 for age ≥60 vs. <35 years), injecting drug use (OR = 1.71; 95% CI: 1.53-1.91 vs. heterosexual intercourse), and CD4 count <50 cells/mm(3) at AIDS diagnosis (OR = 1.87, 95% CI: 1.55-2.27 vs. ≥350). Elevated ORs for early mortality also emerged for PWA diagnosed with primary brain lymphoma (OR = 11.66, 95% CI: 7.32-18.57), or progressive multifocal leukoencephalopathy (OR = 4.21, 95% CI: 3.37-5.27).

Conclusions: Our study documented, among Italian PWA, the high - though slightly decreasing - frequency of early mortality in the full cART era. These findings indicate the need for enduring and ameliorating preventive actions aimed at timely HIV testing among all individuals at risk for HIV infection and/or those who present diseases known to be related with HIV infection.

Citing Articles

Increased kidney disease mortality among people with AIDS versus the general population: a population-based cohort study in Italy, 2006-2018.

Taborelli M, Suligoi B, Serraino D, Frova L, Grande E, Toffolutti F BMJ Open. 2022; 12(12):e064970.

PMID: 36456002 PMC: 9716863. DOI: 10.1136/bmjopen-2022-064970.


Early mortality in a cohort of people living with HIV in Rio de Janeiro, Brazil, 2004-2015: a persisting problem.

Leite P, Coelho L, Cardoso S, Moreira R, Veloso V, Grinsztejn B BMC Infect Dis. 2022; 22(1):475.

PMID: 35581552 PMC: 9115995. DOI: 10.1186/s12879-022-07451-x.


Excess mortality related to circulatory system diseases and diabetes mellitus among Italian AIDS patients vs. non-AIDS population: a population-based cohort study using the multiple causes-of-death approach.

Suligoi B, Virdone S, Taborelli M, Frova L, Grande E, Grippo F BMC Infect Dis. 2018; 18(1):428.

PMID: 30153797 PMC: 6114052. DOI: 10.1186/s12879-018-3336-x.


Impact of comorbidity on the risk and cost of hospitalization in HIV-infected patients: real-world data from Abruzzo Region.

Cammarota S, Citarella A, Manzoli L, Flacco M, Parruti G Clinicoecon Outcomes Res. 2018; 10:389-398.

PMID: 30087571 PMC: 6061204. DOI: 10.2147/CEOR.S162625.


Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.

Parashar S, Collins A, Montaner J, Hogg R, Milloy M Curr Opin HIV AIDS. 2016; 11(5):507-513.

PMID: 27254749 PMC: 5055433. DOI: 10.1097/COH.0000000000000297.


References
1.
Grinsztejn B, Veloso V, Friedman R, Moreira R, Luz P, Campos D . Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS. 2009; 23(16):2107-14. PMC: 3790467. DOI: 10.1097/QAD.0b013e32832ec494. View

2.
Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C . Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther. 2007; 12(1):89-96. DOI: 10.1177/135965350701200111. View

3.
May M, Gompels M, Delpech V, Porter K, Post F, Johnson M . Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011; 343:d6016. PMC: 3191202. DOI: 10.1136/bmj.d6016. View

4.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O . Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 2012; 35(2):113-59. View

5.
Camoni L, Raimondo M, Regine V, Salfa M, Suligoi B . Late presenters among persons with a new HIV diagnosis in Italy, 2010-2011. BMC Public Health. 2013; 13:281. PMC: 3616982. DOI: 10.1186/1471-2458-13-281. View